News Johnson & Johnson BOERSE MUENCHEN

Equities

JNJ

US4781601046

Real-time BOERSE MUENCHEN Other stock markets 04:50:11 2024-05-28 EDT			5-day change	1st Jan Change
135.6 ^EUR	-0.83%		-1.98%	-3.40%

05-24	J&J: to present advances at ASCO and EHA	CF
05-23	Some of the biggest splits in Corporate America	RE

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Johnson & Johnson: Meet a nurse who leads clinical trials to find innovative cancer therapies	05-24	AQ
J&J: to present advances at ASCO and EHA	05-24	CF
Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA	05-24	PU
Some of the biggest splits in Corporate America	05-23	RE
Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies	05-22	RE
Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says	05-22	MT
Top Midday Stories: US Targets August 1 Start Date for China Tariff Hikes; CFPB Says BNPL Requires Credit Card-Level Oversight; Target Shares Fall on Earnings Miss; Third BHP Bid Rejected by Anglo American	05-22	MT
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	05-22	BU
Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says	05-22	MT
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	05-22	AQ
Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship	05-21	MT
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission	05-21	AQ
Novel biologic could offer ulcerative colitis symptomatic remission	05-21	AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	05-21	AQ
J&J: positive trial for Tremfya in ulcerative colitis	05-21	CF
Valneva Names New Chief Scientific Officer	05-21	MT
Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft...	05-20
Ex-dividend day	05-19	FA
J&J-backed startup Rapport files for US IPO	05-17	RE
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Transcript	05-17	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm